BINEX Co., Ltd. (KOSDAQ:053030)

Market Cap	257.97B -48.9%
Revenue (ttm)	164.00B +17.0%
Net Income	-12.86B
EPS	-403.67
Shares Out	31.85M
PE Ratio	n/a
Forward PE	90.41
Dividend	n/a
Ex-Dividend Date	n/a

Volume	141,878
Open	8,020.00
Previous Close	8,100.00
Day's Range	7,740.00 - 8,170.00
52-Week Range	7,420.00 - 19,200.00
Beta	0.66
Analysts	Buy
Price Target	15,200.00 (+93.63%)
Earnings Date	Aug 14, 2026

About BINEX

BINEX Co., Ltd. operates as a pharmaceutical company in South Korea. The company engages in cell line and process development, and analytical method production development. It is also involved in cell cultivation and microbial fermentation modalities process production. In addition, the company offers chemical pharmaceutical products. BINEX Co., Ltd. was founded in 1957 and is headquartered in Busan, South Korea.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1957
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 053030

Financial Performance

In 2025, BINEX's revenue was 168.47 billion, an increase of 29.55% compared to the previous year's 130.05 billion. Losses were -3.23 billion, -90.80% less than in 2024.

Analyst Summary

According to 2 analysts, the average rating for 053030 stock is "Buy." The 12-month stock price target is ₩15,200, which is an increase of 93.63% from the latest price.

Price Target

₩15,200

(93.63% upside)

Analyst Consensus: Buy